Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov 7;13(11):1627-1632.
doi: 10.2215/CJN.04020318. Epub 2018 Sep 4.

Urea for the Treatment of Hyponatremia

Affiliations

Urea for the Treatment of Hyponatremia

Helbert Rondon-Berrios et al. Clin J Am Soc Nephrol. .

Abstract

Background and objectives: Current therapies for hyponatremia have variable effectiveness and tolerability, and in certain instances, they are very expensive. We examined the effectiveness, safety, and tolerability of urea for the treatment of inpatient hyponatremia.

Design, setting, participants, & measurements: We identified all patients hospitalized at the University of Pittsburgh Medical Center between July 2016 and August 2017 with hyponatremia (plasma sodium <135 mEq/L) who received urea, including a subgroup of patients who received urea as the sole drug therapy for hyponatremia (urea-only treated). We matched urea only-treated patients to a group of patients with hyponatremia who did not receive urea (urea untreated) and compared changes in plasma sodium at 24 hours and the end of therapy as well as the proportion of patients who achieved plasma sodium ≥135 mEq/L. We abstracted data on adverse events and reported side effects of urea.

Results: Fifty-eight patients received urea (7.5-90 g/d) over a median of 4.5 (interquartile range, 3-8) days and showed an increase in plasma sodium from 124 mEq/L (interquartile range, 122-126) to 131 mEq/L (interquartile range, 127-134; P<0.001). Among 12 urea only-treated patients, plasma sodium increased from 125 mEq/L (interquartile range, 122-127) to 131 mEq/L (interquartile range, 129-136; P=0.001) by the end of urea therapy. There was a larger increase in plasma sodium at 24 hours in urea only-treated patients compared with urea-untreated patients (2.5 mEq/L; interquartile range, 0-4.5 versus -0.5 mEq/L; interquartile range, -2.5 to 1.5; P=0.04), with no difference in change in plasma sodium by the end of therapy (6 mEq/L; interquartile range, 3.5-10 versus 5.5 mEq/L; interquartile range, 3-7.5; P=0.51). A greater proportion of urea only-treated patients achieved normonatremia, but this difference was not statistically significant (33% versus 8%; P=0.08). No patients experienced overly rapid correction of plasma sodium, and no serious adverse events were reported.

Conclusions: Urea seems effective and safe for the treatment of inpatient hyponatremia, and it is well tolerated.

Keywords: hyponatremia; inappropriate ADH syndrome; urea.

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1.
Figure 1.
Increase in plasma sodium (Na) from baseline to the completion of therapy among urea only–treated patients.

Similar articles

Cited by

References

    1. Waikar SS, Mount DB, Curhan GC: Mortality after hospitalization with mild, moderate, and severe hyponatremia. Am J Med 122: 857–865, 2009 - PMC - PubMed
    1. Deitelzweig S, Amin A, Christian R, Friend K, Lin J, Lowe TJ: Health care utilization, costs, and readmission rates associated with hyponatremia. Hosp Pract (1995) 41: 89–95, 2013 - PubMed
    1. Rondon-Berrios H, Berl T: Mild chronic hyponatremia in the ambulatory setting: Significance and management. Clin J Am Soc Nephrol 10: 2268–2278, 2015 - PMC - PubMed
    1. Greenberg A, Verbalis JG, Amin AN, Burst VR, Chiodo JA 3rd, Chiong JR, Dasta JF, Friend KE, Hauptman PJ, Peri A, Sigal SH: Current treatment practice and outcomes. Report of the hyponatremia registry. Kidney Int 88: 167–177, 2015 - PMC - PubMed
    1. Berl T: Vasopressin antagonists. N Engl J Med 373: 981, 2015 - PubMed

Publication types